Wanbury Ltd (WANBURY) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Wanbury Ltd on NSE and BSE, with an AI summary of each filing.
Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials.
Press Release · 30 Oct 2026, 6:32 pm
Wanbury Receives Australian TGA GMP Compliance Certificate for Tanuku Facility Wanbury Limited secured a Good Manufacturing Practice (GMP) compliance certificate from Australia's Therapeutic Goods Administration (TGA) for its Tanuku manufacturing facility in Andhra Pradesh. Issued on 28th Oct'26 following an inspection conducted on 8th–9th Jun'26, the certification is valid until 9th Dec'28. The approval covers six active pharmaceutical ingredients (APIs): Metformin Hydrochloride, Tramadol Hydrochloride, Sertraline Hydrochloride, Diphenhydramine Hydrochloride, Mefenamic Acid, and Paroxetine Hydrochloride Hemihydrate. The clearance enables TGA to issue GMP clearances to Australian sponsors, facilitating regulated supply into the Australian market.
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited Financial Results (Standalone ....
Intimation · 04 Nov 2026, 5:30 am
Wanbury Limited Schedules Board Meeting on 4th Nov'26 for Q2 Financial Results Wanbury Limited announced that a meeting of its Board of Directors is scheduled for 4th Nov'26 to consider and approve the standalone and consolidated un-audited financial results for the second quarter and half year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and key managerial personnel until 48 hours after the declaration of the financial results.
WANBURY LIMITED has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 04 Nov 2026, 5:30 am
Wanbury Limited Awards for Tanuku and Patalganga Facilities
Press Release · 19 Oct 2026, 8:11 pm
Wanbury Receives Key Safety and Workplace Recognitions for API Facilities Wanbury Limited announced that its Patalganga, Maharashtra API manufacturing site received the "Certificate of Excellence" from the National Safety Council for outstanding safety performance for the third consecutive year on 19th Oct'26. Additionally, its Tanuku, Andhra Pradesh API manufacturing facility was awarded the "Best Employer Award" by the Andhra Pradesh State Government for employee practices and workplace culture. Both USFDA and EUGMP-approved facilities support Wanbury’s global API supply chain across more than 50 export markets.
Wanbury Limited - Regulatory Progress in API Business, New Business Opportunities and Operational Achievements
Press Release · 16 Oct 2026, 6:42 pm
Wanbury Achieves USFDA Milestones and Expands Global Metformin Business Wanbury received nine "No DMF Deficiency" letters from the USFDA across Jul–Aug'26 for Metformin HCl, alongside approvals for Paroxetine and Diphenhydramine HCl. Expanding its API pipeline, the company is validating Quetiapine Fumarate, Sitagliptin, and Empagliflozin, with regulatory filings planned next quarter for semi-regulated markets. In commercial expansions, Wanbury commercialised a Metformin DC business in Saudi Arabia with an annual revenue potential of ~Rs 10 crore, while its customer secured a two-year Metformin supply tender in Mexico valued at ~Rs 15 crore per annum.
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysolftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.
Press Release · 12 Oct 2026, 8:27 pm
Wanbury Enters Paediatric Dermatology Segment with Berrysoft Baby Range Launch Wanbury Skin Health Limited, a subsidiary of Wanbury Limited, launched its berrysoft™ baby skincare range across India on 12th Oct'26, marking its strategic entry into paediatric dermatology. The portfolio includes bathing bars, body wash, shampoo, and handwash, with lotions and diaper creams in the pipeline. The company secured GST registrations across five states and CFA drug licenses in four cities. Wanbury plans to cross-sell to paediatricians and engage dermatologists to expand its branded formulations presence across complementary healthcare categories.
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.
Press Release · 12 Oct 2026, 6:58 pm
Wanbury Enters Paediatric Dermatology Segment with berrysoft Baby Product Launch Wanbury Limited's subsidiary, Wanbury Skin Health Limited, launched its berrysoft baby skincare range across multiple Indian states, marking its strategic entry into paediatric dermatology. The subsidiary secured GST registrations in five states, including Maharashtra, Delhi, and Karnataka, with three more pending, alongside CFA Drug Licenses across Mumbai, Jaipur, Patna, and Ambala, with four in pipeline. The initial rollout includes bathing bars, body wash, shampoo, and handwash, with lotions and diaper rash creams in pipeline, leveraging existing paediatrician networks to drive cross-selling growth.
Press Release regarding filing new Drug Master File (DMF) in South Africa for Tramadol HC1 API.
Press Release · 08 Oct 2026, 6:34 pm
Wanbury Expands Global API Presence with Key Filings and Regulatory Approvals Wanbury Limited filed a new Drug Master File (DMF) in South Africa for Tramadol HCl API, alongside Metformin HCl API DMF filings in the Philippines and Singapore. The company received EDQM approval after adding Key Starting Materials vendors to secure supply chain continuity for its CEP-filed Paroxetine HCl API. Additionally, Australia’s TGA accepted Wanbury’s compliance report for inspectional observations, ensuring uninterrupted API supplies to the Australian market.
Scrutinizer Report and Voting Results
Annual General Meeting · 25 Sept 2026, 9:38 pm
Wanbury Shareholders Approve All Resolutions at 38th AGM Wanbury Limited announced the results of its 38th AGM held on 24th Sep'26. Shareholders approved all four resolutions with requisite majority, achieving a 43.91% overall voting turnout (15,354,856 total votes polled across 34,966,928 shares). Key approvals include the adoption of FY26 audited financial statements (~100% votes in favour), the re-appointment of retiring director Mr. K. Chandran (~100% in favour), the ratification of cost auditor remuneration for FY27 (~100% in favour), and the special resolution for re-appointing Whole-time Director Mr. Mohan Kumar Rayana beyond age 70 (99.94% overall approval).
Change in Management
Change in Management · 25 Sept 2026, 1:47 am
Wanbury Approves Whole-Time Director Re-Appointment and Cost Auditor Wanbury Limited announced that shareholders approved key resolutions at its 38th AGM on 24th Sep'26. The company approved the re-appointment and continuation of Mohan Kumar Rayana as Whole-time Director beyond age 70 for a five-year term from 21st Aug'26 to 20th Aug'31. Additionally, shareholders approved the appointment and remuneration of M/s. ABK & Associates, Cost Accountants, as Cost Auditor for FY27. Rayana holds over 25 years of advisory experience with Wanbury, overseeing business strategy, general management, fund raising, and debt settlement.
Proceedings of the 38th Annual General Meeting of the Company held on Thursday, September 24, 2026 through VC/OAVM
Annual General Meeting · 25 Sept 2026, 1:29 am
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.
Others (Uncategorized) · 01 Sept 2026, 12:17 am
Notice of the 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).
Annual General Meeting · 01 Sept 2026, 12:05 am
Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.
Press Release · 13 Aug 2026, 6:17 pm
Wanbury Secures Key European and US Regulatory Approvals Wanbury Limited announced on 13 Aug '26 it received EDQM approval for its Rivaroxaban API, opening access to EU markets. This positions the company to meet customer demand in the EU and other CEP-accepting countries. Additionally, Wanbury received USFDA DMF clearance for Paraxetine HCl and Metformin HCl. These APIs are currently under ANDA review for multiple customers, indicating a strengthening product pipeline for the US market and potential for future revenue streams from key regulated territories.
Outcome of the Board Meeting held on August 11, 2026
Others (Uncategorized) · 12 Aug 2026, 2:44 am
Wanbury Board Approves Q1 Results, ESOP Allotment, and Director Re-appointment Wanbury's board approved Q1'FY27 results on 11 Aug'26, reporting a profit after tax of ₹324.29 lakhs, down from ₹1,349.05 lakhs YoY. Revenue from operations stood at ₹16,558.35 lakhs, a 1.5% YoY increase. The board also allotted 27,530 equity shares under its ESOP 2016 plan, increasing paid-up capital to ₹34.96 crore. Additionally, the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a five-year term starting 21 Aug'26 was approved, subject to shareholder consent.
Press Release on Un-audited Financial Results for the quarter ended 30th June, 2026
Press Release · 12 Aug 2026, 2:40 am
Wanbury's Q1 FY27 PAT Drops 76% YoY on Margin Pressure Wanbury reported Q1 FY27 results with revenue at Rs. 165.6 Cr, up 1.5% YoY, impacted by API export delays from West Asia logistics issues. EBITDA fell 33.0% YoY to Rs. 16.6 Cr, with margins contracting 517 bps to 10.0% due to higher raw material costs. PAT declined 76.0% YoY to Rs. 3.2 Cr. Key positives include successful debt refinancing, which will lower borrowing costs from 12.5% to sub-10% starting Q2 FY27, and release of promoter pledged shares. Regulatory inspections by TGA and MFDS were cleared.
Outcome of the Board Meeting held on August 11, 2026
Change in Management · 12 Aug 2026, 2:34 am
Wanbury Board Meeting: Q1FY27 Results, ESOP Allotment, and Director Re-appointment Wanbury reported Q1FY27 results on 11 Aug'26 with revenue at ₹16,558.35 lakhs and Profit After Tax (PAT) of ₹324.29 lakhs. This represents a 1.5% YoY revenue growth but a 76% YoY PAT decline from ₹1,349.05 lakhs. The board approved allotting 27,530 equity shares under its ESOP 2016 at ₹10/share, increasing paid-up capital to ₹34.97 crore. The board also approved the re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for five years, effective 21 Aug'26, subject to shareholder approval.
Financial Results for the first quarter ended 30th June, 2026
Financial Result · 12 Aug 2026, 2:29 am
Wanbury Reports Q1FY27 Results, Announces ESOP Allotment and Director Re-appointment Wanbury reported Q1FY27 results on 11 Aug'26 with revenue from operations at ₹16,558.35 lakhs and profit after tax (PAT) at ₹324.29 lakhs, a significant decline from ₹2,170.49 lakhs QoQ and ₹1,349.05 lakhs YoY. Basic EPS stood at ₹0.93. The board also approved the allotment of 27,530 equity shares under its ESOP 2016 plan, increasing the paid-up share capital to ₹34,96,69,280. Additionally, Mr. Mohan Kumar Rayana was re-appointed as Whole-time Director for five years, effective 21 Aug'26.
Outcome of the Board Meeting held on August 11, 2026
Outcome · 12 Aug 2026, 2:20 am
Wanbury Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 16,558 (+1.5% YoY | +0.6% QoQ) ■ EBITDA: 1,624 (-33.6% YoY | -45.6% QoQ) ■ EBITDA Margin (%): 9.8 (-517 bps YoY | -833 bps QoQ) ■ PAT: 324 (-76.0% YoY | -85.1% QoQ) ■ EPS (INR): 0.92 (-76.7% YoY | -85.5% QoQ)
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....
Intimation · 11 Aug 2026, 5:30 am
Wanbury Board Meeting Scheduled for Q1 FY27 Results Wanbury Limited has scheduled a Board of Directors meeting on 11th Aug'26 to consider and approve the un-audited financial results for the first quarter ended 30th Jun'26. In compliance with SEBI regulations, the trading window for designated persons will remain closed until 48 hours after the results are declared.
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs
Press Release · 30 Jul 2026, 3:41 pm
Wanbury Receives Favorable USFDA Update for Metformin API Wanbury Limited announced on 30th Jul'26 that it received a "No DMF deficiency letter" from the USFDA for multiple Abbreviated New Drug Applications (ANDAs). This key regulatory clearance pertains to formulations using its Metformin HCl Active Pharmaceutical Ingredient (API), signaling full compliance with US standards. The positive development clears a significant regulatory hurdle for the company's US-focused products. The company also noted a recent DMF filing to expand its API business opportunities into the South Korean market.
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company''s Facilty.
Others (Uncategorized) · 22 Jul 2026, 8:45 pm
Wanbury Receives USFDA Form 483 with Six Observations for Tanuku Facility Wanbury Limited announced the completion of a routine cGMP inspection by the USFDA at its Tanuku facility from Jul 13 to Jul 17, '26. The inspection concluded with the issuance of a Form 483 containing six observations. The company believes the observations are addressable through corrective actions and documentation. Management does not anticipate any material impact on its operations, exports to the US, or overall financial performance arising from this inspection. Wanbury will respond to the FDA within the stipulated timeframe.
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company''s facility at Tanuku, West Godavari District, ....
Others (Uncategorized) · 20 Jul 2026, 9:44 pm
Wanbury Receives USFDA Form 483 with Six Observations for Tanuku Facility Wanbury Limited received a Form 483 with six observations from the USFDA following a routine cGMP inspection at its Tanuku facility in Andhra Pradesh. The inspection was conducted from Jul 13, '26 to Jul 17, '26. The company stated it will respond to the observations within the stipulated timeframe. This development is a key regulatory overhang, with the resolution of the observations critical for future product approvals and supplies to the US market. The number and nature of observations will be closely monitored.
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent ....
Others (Uncategorized) · 17 Jul 2026, 6:59 pm
Wanbury Cites Market Forces for Recent Stock Price Movement In response to a stock exchange inquiry dated Jul 16, 2026, regarding significant price movement, Wanbury Limited clarified on Jul 17, 2026, that the increase is completely market-driven. The company confirmed it has no undisclosed material events or information to report at this time. Wanbury stated that all required disclosures under SEBI (LODR) Regulations have already been made and committed to future compliance. This response suggests no company-specific event is behind the recent stock rally.